🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Out now In Heart Failure Reviews! We discuss the role of #MachineLearning in the prevention of #heartfailure. link.springer.com/article/10.100… Matt Segar BiykemBozkurt Carlos G Santos-Gallego, MD vijay nambi Michael Hall Javed Butler Marat Fudim, MD MHS Tweetorial👇👇👇

Important 2-yr from the REVIVAL registry now in JACC Journals #JACCHF ✅ Natural hx/trajectory of pts w/ Advanced Ambulatory HF (~90% INTERMACS 5-7) ⬇️⬇️ 📎 jacc.org/doi/10.1016/j.…

The SCN5A gene, crucial for cardiac action potential, has been linked to more than just channelopathies— it may play a role in cardiomyopathy. SCN5A variants impact heart muscle, merging electrical & contraction pathways. Bench to bedside in #HREV (link.springer.com/article/10.100…).

Wow! Practice changing EARLY TAVR RCT. For a long time, we waited for aortic stenosis patients to become symptomatic before considering therapy, based on old data (risk of surgery vs watchful waiting). ASYMPTOMATIC patients with severe AS, TAVR leads to a major reduction in MACE

HyperK, a life-threatening condition common in HF, CKD, DM, and HTN, is challenging to manage. New potassium binders like patiromer & SZC are transforming care, offering rapid, sustained K+ reduction to enable GDMT with better tolerability. Now in #HREV (link.springer.com/article/10.100…).

All core #GDMT ↓ all-cause🏥in HF 👇🏾 #SGLT2i 4 RCTs JACC Journals sciencedirect.com/science/articl… RR 0.89 (0.84-0.93) P<0.001 #ARNI 2 RCTs JAMA Cardiology jamanetwork.com/journals/jamac… HR 0.92 (0.88-0.97) P=0.002 #nsMRA 3 RCTs Nature Medicine nature.com/articles/s4159… HR 0.95 (0.91-0.99) P=0.025

Should polypharmacy in older adults dissuade treatment optimization in heart failure? No. Contrary to common clinical beliefs, randomized data of core #GDMT suggests efficacy is greater, not lesser, among those on a large # of background medicines. 👇🏾

HFpEF remains a challenge: poor QoL and functional capacity. While reducing sympathetic activity, beta-blockers may worsen exercise tolerance. Evidence on outcomes is mixed, especially in HFpEF + AF. We need RCTs! Read now in #HREV (link.springer.com/article/10.100…). Parag Goyal MD MSc

AMI-CS remains a high-mortality condition despite advancements in treatment. The DanGer Shock trial is the first positive RCT for MCS in AMI-CS. Key factors: optimal patient phenotype, timely MCS deployment, and rigorous care protocols (link.springer.com/article/10.100…). Read now in #HREV

NLP is revolutionizing HF. By processing vast amounts of untapped textual data from EHRs, NLP improves cohort assembly, disease phenotyping, and outcome assessment in research. Now in #HREV (link.springer.com/article/10.100…). Kaiser Permanente NorCal Cardiology Fellowship Steven A. Hamilton Rishi Parikh Matthew Solomon, MD, PhD Alan Go

Excellent SOTA review in JACC Journals #JACCAdv led by Elliott Miller on contemporary evaluation & management of decompensated #valve disease in the #CICU.🗝️ figures essential for all CV #FITs with an interest in critical care cardiology! BalimSenman Ann Gage venu menon

PRO-HF trial tested if routine use of KCCQ in HF clinics improves QoL. No significant difference in QoL or clinical outcomes at 1 year. Future work needed to optimize PRO integration. Summary in #HREV (link.springer.com/article/10.100…). Mario Enrico Canonico Marc Samsky Alex Sandhu Jimmy Zheng

Is 70 the age that we should be using for a cutoff of #HeartTransplantation? These results show excellent survival outcomes from the SRTR registry in our oldest recipients in the U.S. Erik Henricksen 🔗: jhltonline.org/article/S1053-…

HFpEF remains a major challenge in CVD, marked by diastolic dysfunction & limited therapies. SERCA2a, key to Ca2+ regulation, may play a role in its pathophysiology. This SoTA #HREV (link.springer.com/article/10.100…) explores mechanisms, trials, & potential links with SGLT2i/GLP-1 drugs.

Transcatheter Tricuspid Valve Replacement: JACC Journals 🥸 Nice clinical review 😱 Please take a look: good morning 👇👇👇

We’ve all faced hard decisions about accepting donor hearts with LV dysfunction: will it be reversible? Biomarkers can help you make this decision, particularly ntproBNP levels: check out the latest from the Donor Heart Study: onlinelibrary.wiley.com/doi/10.1002/ej… Brian Wayda Stanford Heart Failure, Cardiac Transplant and MCS

HFpEF remains tough to treat—with high residual risk & few meds that work. Device-based therapies offer new hope, targeting unique mechanisms (structural, autonomic, EP, RPM). Great summary by friend & former co-fellow Marat Fudim, MD MHS! link.springer.com/article/10.100… Read #HREV Mark Kittipibul MD

WHF is moving from hospital to home. Outpatient options like SQ furosemide & IN bumetanide show promise for safe, effective diuresis—but hurdles remain: training, logistics, patient education, & limited data. (link.springer.com/article/10.100…) #HREV Steve Greene Marat Fudim, MD MHS Andrew J Sauer MD

Many patients with HF still suffer despite meds & devices. Between GDMT and HT/LVAD, a treatment gap remains. This review highlights FDA-approved options—cardiac contractility modulation & baroreceptor activation—to bridge that gap (link.springer.com/article/10.100…) #HREV Marat Fudim, MD MHS

Obesity and inflammation drive HF, yet no targeted therapies had improved outcomes—until now. Early trials show promise; larger studies underway may soon redefine the management of HF. Read now in #HREV (link.springer.com/article/10.100…). Jan Biegus Javed Butler Marco Metra Dr. Deepak L. Bhatt